Tranexamic Acid in Hip and Knee Arthroplasty

Area of Science:

• Orthopedic Surgery
• Anesthesiology
• Pharmacology

Background:

• Perioperative blood loss is a significant concern in total joint arthroplasty (TJA).
• Tranexamic acid (TXA) is an antifibrinolytic agent that inhibits clot degradation.
• Evidence supports TXA's efficacy in reducing blood loss and transfusion requirements in hip and knee arthroplasty.

Purpose of the Study:

• To review the evidence on the effectiveness of tranexamic acid (TXA) in total joint arthroplasty.
• To discuss optimal administration routes and dosing regimens for TXA.
• To assess the safety profile of TXA in arthroplasty patients.

Main Methods:

• Review of existing literature on tranexamic acid (TXA) in hip and knee arthroplasty.
• Analysis of studies investigating intravenous (IV) and topical administration of TXA.
• Evaluation of different dosing strategies and their impact on blood loss and transfusion rates.

Main Results:

• Both IV and topical TXA administration are effective in reducing perioperative blood loss and transfusion requirements.
• An initial IV dose before surgery followed by at least one postoperative IV dose is recommended.
• Topical TXA doses exceeding 2 g appear more efficacious than lower doses; few adverse events and no increased VTE risk reported.

Conclusions:

• Tranexamic acid (TXA) is a safe and effective adjunct for managing blood loss in total joint arthroplasty.
• Further research is needed to define optimal dosing regimens.
• Current evidence supports the use of TXA to minimize transfusions and improve patient outcomes.